Abstract 1529P
Background
High recurrence and metastasis rates remain the main factors leading to the failure of the current standard treatment of neoadjuvant chemoradiotherapy plus surgery for resectable locally advanced ESCC. Improving the pathological complete response (pCR) rate may significantly benefit the survival of patients with resectable locally advanced ESCC after neoadjuvant therapy.
Methods
Patients aged 18-75 years with untreated, resectable, stage III-IVA ESCC, adequate organ and bone marrow function were eligible for inclusion. patients received neoadjuvant chemoradiotherapy (paclitaxel 135 mg/m2 d1 + carboplatin AUC = 3–5 d1, q3w × 2 cycles + 65 simultaneous radiotherapy (40 Gy/4 W/20F)) treatment, after the end of chemoradiotherapy, Tislelizumab (200 mg intravenously every 3 weeks for 2 cycles, and all patients undergo surgery after 4–6 weeks. The primary outcomes of the pCR rate and the incidence of adverse events will be analyzed completely within months, the secondary endpoints will include major pathological response rate, objective response rate, R0 resection rate, event-free survival, and overall survival. All enrolled patients were included in the activity and safety analyses.
Results
Thirty-two patients were enrolled in the study, among 8 patients are waiting for a surgery, with 24 patients undergoing surgical resection at a 100% R0 resection rate. All patients had stage III-IVA disease. Patients who received tislelizumab plus chemotherapy sequential nCRT achieved 13(54.2%) patients had a pathologic complete response, 16 (66.7%) patients achieved major pathologic response, and 21(87.5%) objective remission rate. Within 30 days after surgery, anastomotic fistula was found in 4 (16.7%) patients, but no deaths occurred, the most common grade 2 or 3 adverse event was leukopenia, hypothyroidism and lymphopenia. The analysis of survival was immature, and patients are still being followed up.
Conclusions
This study explored the safety and efficacy of tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy for ESCC patients and provided a total neoadjuvant therapy model that can benefit patients with locally advanced ESCC.
Clinical trial identification
NCT05189730.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21